AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05110144
Drug: Duloxetine 60 MG
RxNorm normalized name: duloxetine 60 MG
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg orally for 4 weeks
Trial: NCT05110144
Drug: Amitriptyline 25 MG
RxNorm normalized name: amitriptyline 25 MG
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg orally for 4 weeks
Trial: NCT05110144
Drug: Amitriptyline 50 MG
RxNorm normalized name: amitriptyline 50 mg oral tablet
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg orally for 4 weeks
Trial: NCT04510636
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Trial: NCT04510636
Drug: Bendamustine Hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
Trial: NCT06118086
Drug: REM-422
RxNorm normalized name: REM-422
DrugBank: REM-422 (DB19304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily
Trial: NCT06290063
Drug: fsCBD Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
Trial: NCT06290063
Drug: bsCBD Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
Trial: NCT04784767
Drug: Sodium chloride, USP, for injection (0.9% NaCl)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline will be provided in a sterile, single-use 10 mL vial
Trial: NCT06799000
Drug: Remibrutinib Dose A
RxNorm normalized name: Ibrutinib
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remibrutinib Dose A (oral)
Trial: NCT06799000
Drug: Remibrutinib Dose B
RxNorm normalized name: Remibrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remibrutinib Dose B (oral)
Trial: NCT05234619
Drug: Group three ( lidocaine or control LL ) Late deflation
RxNorm normalized name: three-lobe sage extract
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
Trial: NCT04705844
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
Trial: NCT05802342
Drug: Monosialotetrahexose ganglioside sodium injection
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
Trial: NCT06361316
Drug: Irinotecan liposome injection
RxNorm normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative adjuvant therapy
Trial: NCT05001763
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
Trial: NCT06524518
Drug: Chemotherapy combined with immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy
Trial: NCT05697107
Drug: Ripretinib Oral Tablet
RxNorm normalized name: ripretinib Oral Tablet
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral kinase inhibitor
Trial: NCT00000750
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05066607
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
Trial: NCT06703463
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.
Trial: NCT05667415
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
Trial: NCT04757675
Drug: S-ketamine 0.3
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3 μg/kg intravenous injection s-ketamin
Trial: NCT04757675
Drug: S-ketamine 0.5
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 μg/kg intravenous injection s-ketamin
Trial: NCT04757675
Drug: S-ketamine 2
RxNorm normalized name: (S)-(-)-ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 μg/kg intranasal s-ketamin
Trial: NCT04757675
Drug: S-ketamine 1+Dexmedetomidine 1
RxNorm normalized name: (S)-(-)-ketamine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
Trial: NCT04757675
Drug: S-ketamine 0.5 +Dexmedetomidine 2
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
Trial: NCT06391190
Drug: Albumin-Bound Paclitaxel, cisplatin, Sintilimab
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
Trial: NCT06522984
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.
Trial: NCT05672394
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine
Trial: NCT06487858
Drug: BGB-R046
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT06487858
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT05154968
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC infusion.
Trial: NCT05154968
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC infusion.
Trial: NCT05876832
Drug: Salvage Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
Trial: NCT05350371
Drug: Pirfenidone Oral Tablet
RxNorm normalized name: pirfenidone Oral Tablet
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.
Trial: NCT05813665
Drug: Narlumosbart
RxNorm normalized name: Narlumosbart
DrugBank: Narlumosbart (DB19002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
Trial: NCT05813665
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
Trial: NCT05984784
Drug: IMG-007
RxNorm normalized name: IMG-7289
DrugBank: IMG-7289 (DB15126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IMG-007 Intravenous Infusion
Trial: NCT05045950
Drug: Memantine -Twice Daily or Extended Release
RxNorm normalized name: clindamycin
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4).
Trial: NCT04910477
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
Trial: NCT04910477
Drug: Neostigmine/atropine
RxNorm normalized name: neostigmine/atropine sulfate INJECTION SYRINGE (ML)
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
Trial: NCT05593549
Drug: Trehalose
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Trial: NCT06406153
Drug: Antihistamine
RxNorm normalized name: Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An antihistamine is administered one hour before the infusion.
Trial: NCT03068832
Drug: Poly ICLC
RxNorm normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.
Trial: NCT05194995
Drug: JAB-21822
RxNorm normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAB-21822 administered orally as a tablet.
Trial: NCT05194995
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab administered as an intravenous (IV) infusion.
Trial: NCT06563895
Drug: Acoramidis
RxNorm normalized name: Acoramidis
DrugBank: Acoramidis (DB17999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTR stabilizer administered orally twice daily (BID)
Trial: NCT01418534
Drug: Torrent's Isosorbide Mononitrate 120 mg ER Tablets
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05284032
Drug: isatuximab 10 mg/kg
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by intravenous infusion
Trial: NCT06491108
Drug: Vardenafil 5 Mg Oral Tablet
RxNorm normalized name: vardenafil 5 MG Oral Tablet
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
Trial: NCT05753397
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
Trial: NCT06336174
Drug: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
Trial: NCT06462469
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
Trial: NCT05633667
Drug: Zimberelimab (ZIM)
RxNorm normalized name: lidocaine
DrugBank: Zimberelimab (DB17505)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05633667
Drug: Domvanalimab (DOM)
RxNorm normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05633667
Drug: Sacituzumab govitecan-hziy (SG)
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT05633667
Drug: Etrumadenant (ETRUMA)
RxNorm normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05633667
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05633667
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05633667
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT05633667
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05633667
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05633667
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05633667
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT06638671
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
Trial: NCT05606913
Drug: dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide administered subcutaneously (SC) once a week.
Trial: NCT06153251
Drug: BMS-986453
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06153251
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06435260
Drug: Camrelizumab+chemotherapy
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles.
Trial: NCT06561152
Drug: Tagraxofusp
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)
Trial: NCT06561152
Drug: Cladribine (CLAD)
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)
Trial: NCT06561152
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)
Trial: NCT05349890
Drug: CDX-1140
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant fully human IgG2κ monoclonal antibody
Trial: NCT05349890
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized immunoglobulin G4 (IgG4) monoclonal antibody
Trial: NCT05891964
Drug: Secukinumab Injection
RxNorm normalized name: Secukinumab Injection
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
Trial: NCT06798402
Drug: Ciprofloxacin (BAYO9867)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).
Trial: NCT06798402
Drug: sodium stibogluconate (Pentostam)
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional sodium stibogluconate (100 mg/ml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg/cm2)
Trial: NCT05870579
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg once daily (OD) days 1 to 21 every 28 days
Trial: NCT05870579
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter
Trial: NCT05511623
Drug: tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
Trial: NCT05121363
Drug: Anlotinib Hydrochloride capsules
RxNorm normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
Trial: NCT04842032
Drug: KRN23
RxNorm normalized name: Burosumab
DrugBank: Burosumab (DB14012)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
Trial: NCT05887908
Drug: co-administration of cefepime and nacubactam
RxNorm normalized name: cefepime and amikacin
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 g cefepime and 1 g nacubactam
Trial: NCT05887908
Drug: co-administration of aztreonam and nacubactam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 g aztreonama and 1 g nacubactam